Comparative evaluation of BD phoenix and Vitek 2 systems for species identification of common and uncommon pathogenic yeasts

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3841-3845

  Posteraro, Brunella ^a   Ruggeri, Alberto ^a   De Carolis, Elena ^a   Torelli, Riccardo ^a   Vella, Antonietta ^a   De Maio, Flavio ^a   Ricciardi, Walter ^a   Posteraro, Patrizia ^b   Sanguinetti, Maurizio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ospedale San Carlo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; INTERNAL TRANSCRIBED SPACER;

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ANALYTICAL ERROR; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BD PHOENIX SYSTEM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; DATA BASE; DNA SEQUENCE; FUNGAL DETECTION; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS GROWTH; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VITEK 2 SYSTEM; YEAST;

HUMANS; MICROBIOLOGICAL TECHNIQUES; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOLOGY; MYCOSES; YEASTS;

EID: 84886480453     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01581-13     Document Type: Article

References (31)

1. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
2. Arendrup MC. 2010. Epidemiology of invasive candidiasis. Curr. Opin. Crit. Care 16:445-452.
3. Miceli MH, Díaz JA, Lee SA. 2011. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11:142-151.
4. Falagas ME, Roussos N, Vardakas KZ. 2010. Relative frequency of albicans and the various non-Albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis. 14:e954-e966.
5. Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M. 2012. The changing epidemiology of healthcare-Associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73:45-48.
6. Chen SC, Marriott D, Playford EG, Nguyen Q, Ellis D, Meyer W, Sorrell TC, Slavin M, Australian Candidaemia Study. 2009. Candidaemia with uncommon Candida species predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin. Microbiol. Infect. 15:662-669.
7. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. 2012. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn. Microbiol. Infect. Dis. 73: 293-300.
8. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. 2013. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J. Med. Microbiol. 62:10-24.
9. Miranda-Zapico I, Eraso E, Hernandez-Almaraz JL, López-Soria LM, Carrillo-Muñoz AJ, Hernandez-Molina JM, Quindós G. 2011. Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital. J. Antimicrob. Chemother. 66:2315-2322.
10. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J. Clin. Microbiol. 50:3435-3442.
11. Garcia-Effron G, Canton E, Peman J, Dilger A, Roma E, Perlin DS. 2012. Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J. Antimicrob. Chemother. 67:2739-2748.
12. Peman J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G; FUNGEMYCA Study Group. 2012. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J. Antimicrob. Chemother. 67: 1181-1187.
13. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, AmarCand Study Group. 2009. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit. Care Med. 37: 1612-1618.
14. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Müller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ. 2009. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 35:55-62.
15. Caira M, Trecarichi EM, Tumbarello M, Leone G, Pagano L. 2011. Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Rev. Anti Infect. Ther. 9:1067-1075.
16. Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y. 2010. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65:1460-1465.
17. Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. 2012. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia 174:259-271.
18. Castanheira M, Woosley LN, Diekema DJ, Jones RN, Pfaller MA. 2013. Candida guilliermondii and other species of candida misidentified as Candida famata: assessment by Vitek 2,DNAsequencing analysis, and matrixassisted laser desorption ionization-time of flight mass spectrometry in two global antifungal surveillance programs. J. Clin. Microbiol. 51:117-124.
19. Posteraro B, De Carolis E, Vella A, Sanguinetti M. 2013. MALDI-TOF mass spectrometry in the clinical mycology laboratory: identification of fungi and beyond. Expert Rev. Proteomics 10:151-164.
20. Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G, Fadda G, Posteraro B. 2007. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J. Clin. Microbiol. 45:1343-1346.
21. White TJ, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p 315-322. In Innis MA, Gelfand DH, Sninsky JJ, White TJ (ed), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.
22. Meletiadis J, Arabatzis M, Bompola M, Tsiveriotis K, Hini S, Petinaki E, Velegraki A, Zerva L. 2011. Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. J. Clin. Microbiol. 49:2722-2727.
23. Majors ML, Robinson A. 2012. Evaluation of the Phoenix YEAST ID for the automated identification of yeast isolates, abstr P-1221. Abstr. 112th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
24. Morgan M, Urquiza Y, Tracey J, Nwosu O. 2012. Comparative evaluation of the BD Phoenix YEAST ID panel and the Vitek2 colorimetric yeast identification card for identification of yeast isolated from clinical samples, abstr P-1220. Abstr. 112th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
25. Cantón E, Peman J, Quindós G, Eraso E, Miranda-Zapico I, alvarez M, Merino P, Campos-Herrero I, Marco F, de la Pedrosa EG, Yagüe G, Guna R, Rubio C, Miranda C, Pazos C, Velasco D, FUNGEMYCA Study Group. 2011. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob. Agents Chemother. 55:5590-5596.
26. del Pilar Vercher M, García Martínez JM, Cantón E, Peman J, Gómez García MM, Gómez EV, del Castillo Agudo L. 2011. Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron. Int. J. Med. Microbiol. 301:531-535.
27. Garcia-Effron G, Canton E, Peman J, Dilger A, Roma E, Perlin DS. 2011. Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J. Clin. Microbiol. 49:3257-3261.
28. Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, Diekema DJ. 2009. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J. Clin. Microbiol. 47:1216-1217.
29. Karthaus M, Rüping MJ, Cornely OA, Steinbach A, Groll AH, Lass- Flörl C, Ostermann H, Ruhnke M, Vehreschild JJ. 2011. Current issues in the clinical management of invasive Candida infections-The AGIHO, DMykG,Ö GMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54:e546-e556.
30. Ostrosky-Zeichner L. 2012. Invasive mycoses: diagnostic challenges. Am. J. Med. 125:S14-S24.
31. Posteraro B, Torelli R, De Carolis E, Posteraro P, Sanguinetti M. 2011. Update on the laboratory diagnosis of invasive fungal infections. Mediterr. J. Hematol. Infect. Dis. 3:e2011002.